Bicycle-Genentech Immuno-oncology Program

The Bicycle-Genentech Immuno-oncology Program is a strategic research and development collaboration between Bicycle Therapeutics and Genentech (a subsidiary of Roche). Established in February 2020, the partnership aims to discover, develop, and commercialize bicyclic peptide-based therapies (Bicycles) for a range of immuno-oncology targets. The collaboration utilizes Bicycle's proprietary phage display platform to identify high-affinity, synthetic bicyclic peptides that can modulate immune system components to treat cancer. While Bicycle Therapeutics is responsible for discovery and early development, Genentech retains options for further development and commercialization. As of the latest reports, the specific molecular targets and individual drug candidates within this program remain undisclosed.